Porsolt and KWS BioTest Collaborates to Provide Preclinical Evaluation in Inflammation and Immunology
News May 05, 2010
Porsolt and KWS announced they have entered into a co-marketing agreement to promote a common catalogue of preclinical tests in the area of inflammation and immunology.
The partnership enables Porsolt and KWS to deliver a complete cascade of tests to evaluate drug candidates, from simple screening assays to more complex models with high translational value. The combination of the expertise of skilled teams of scientists working in both companies will provide customers with integrated solutions for highly efficient discovery & development of their drug candidates in these important therapeutic domains with large unmet needs.
Dr. Martine Lemaire, Senior Director, Commercial & Business Development of Porsolt said, "Porsolt is delighted to be entering into this strategic partnership with KWS. The combination of Porsolt’s expertise in functional readouts with KWS’s expertise in bioanalysis will bring a tremendous added-value to the models we are offering to our customers. This partnership enables us to expand our capabilities in the area of inflammation and immunology, answering the needs expressed by our customers. We are convinced that the synergy between our two companies will benefit our customers. Indeed, it is clear that KWS share our core values of scientific excellence and focusing on customer needs.”
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE